Celebrating 10 Years of Calprotectin Testing in the UK

2017 marks the 10th anniversary of Alpha Laboratories working in partnership with BÜHLMANN to develop the use of calprotectin analyses in the UK. During this time, the role of calprotectin in healthcare pathways has advanced and calprotectin has become established as the current major biomarker for Inflammatory Bowel Diseases (IBD) such as Ulcerative Colitis and Crohn’s Disease. This development was strengthened in October 2013 with the publication of the NICE guidance (DG11), supporting the use of calprotectin as a cost effective method to differentiate between IBD and Irritable Bowel Syndrome (IBS).

Since then, calprotectin testing in the UK has increased dramatically, and BÜHLMANN has expanded its product portfolio to assist with evolving hospital requirements. BÜHLMANN offers the widest available range of calprotectin assays and sample preparation formats, giving flexible solutions that allow hospitals to advance their calprotectin service appropriate to changing demands.

Correlation
Throughout the last decade BÜHLMANN calprotectin assays have been used in many studies in institutions across the world. This large body of work has demonstrated the correlation of the calprotectin concentration to the level of mucosal healing and patients’ clinical outcomes. As a result, BÜHLMANN has one of the most comprehensive reference resources available that validate the use of its range of assays in a variety of settings and applications. There are over 50 references citing the BÜHLMANN fCAL® ELISA.

Standardisation
All the BÜHLMANN assays are standardised with the same degree of metrological rigour giving consistent data and allowing harmony of cut-off concentrations across the various platforms (Figure 1). This allows laboratories to change technologies as their calprotectin request volumes increase with transfer of results across time and geography assured.

The standardisation of the BÜHLMANN assays has remained unchanged for the last 10 years as highlighted in Figure 2, showing data from reference control samples tested during that time period:

It is this consistency, combined with the quality and flexibility of the products, that makes BÜHLMANN such a trusted partner for calprotectin assays.

Future-proof Your Calprotectin Testing with BÜHLMANN

2017 marks the 10th anniversary of Alpha Laboratories working in partnership with BÜHLMANN to develop the use of calprotectin analyses in the UK. During this time, the role of calprotectin in healthcare pathways has advanced and calprotectin has become established as the current major biomarker for Inflammatory Bowel Diseases (IBD) such as Ulcerative Colitis and Crohn’s Disease. This development was strengthened in October 2013 with the publication of the NICE guidance (DG11), supporting the use of calprotectin as a cost effective method to differentiate between IBD and Irritable Bowel Syndrome (IBS).

Since then, calprotectin testing in the UK has increased dramatically, and BÜHLMANN has expanded its product portfolio to assist with evolving hospital requirements. BÜHLMANN offers the widest available range of calprotectin assays and sample preparation formats, giving flexible solutions that allow hospitals to advance their calprotectin service appropriate to changing demands.

Correlation
Throughout the last decade BÜHLMANN calprotectin assays have been used in many studies in institutions across the world. This large body of work has demonstrated the correlation of the calprotectin concentration to the level of mucosal healing and patients’ clinical outcomes. As a result, BÜHLMANN has one of the most comprehensive reference resources available that validate the use of its range of assays in a variety of settings and applications. There are over 50 references citing the BÜHLMANN fCAL® ELISA.

Standardisation
All the BÜHLMANN assays are standardised with the same degree of metrological rigour giving consistent data and allowing harmony of cut-off concentrations across the various platforms (Figure 1). This allows laboratories to change technologies as their calprotectin request volumes increase with transfer of results across time and geography assured.

The standardisation of the BÜHLMANN assays has remained unchanged for the last 10 years as highlighted in Figure 2, showing data from reference control samples tested during that time period:

It is this consistency, combined with the quality and flexibility of the products, that makes BÜHLMANN such a trusted partner for calprotectin assays.

Find out more at www.calprotectin.co.uk

Figure 1. Comparison of ELISA and POCT FC concentrations in follow-up of a patient

Figure 2. Reference control samples BÜHLMANN fCAL® ELISA: June 2006 - March 2017